Adenosine deaminase (ADA) and 5'-nucleotidase (5'-NT) activities were measured in sera of patients with ovarian cancer and patients with benign ovarian tumour. The results were compared with that of a control group consisting of healthy women. ADA levels were significantly increased (P<0.001) in the ovarian cancer group (n=50) but not in the benign group (n=28) when compared to the controls (n=20). The results indicate that ADA and 5'-NT levels may help to differentiate malignant conditions from benign tumours of the ovary in addition to the existing tests such as serum CA-125 levels and histopathological study.
INTRODUCTION
Changes in the levels of adenosine deaminase (ADA) and 5'-nucleotidase (5'-NT), both being the enzymes involved in nucleotide breakdown, is expected to occur in malignant conditions of any tissue. Likewise, increased ADA activity in serum and tumour tissues has been reported in cancer conditions of various tissues like skin, breast and colon (1, 2, 3) . Similarly serum 5'-NT level is reported to be elevated in cancers of the ovary (4) and liver (5, 6) .
However, the studies done regarding 5'-NT in ovarian cancer are very few (4). We could not get any report on ADA levels in ovarian cancer. Hence the present study was conducted with the objective of evaluating the usefulness of measuring serum ADA and 5'-NT levels in ovarian cancer.
MATERIALS AND METHODS
The study was carried out in the year of 2001-2003 for a period of 16 months and the patients were selected from the population attending the Kasturba Hospital, Manipal. Our study comprised of the following three groups: 2. Benign ovarian tumour group: Consisted of cystadenoma patients (n=28).
3. Control group: Consisted of healthy women of different ages abov.e 22 years (n=20).
Specimen
The blood samples were collected without anticoagulant before starting any treatment in the patient groups. Serum was used for the biochemical analyses.
METHODS
The biochemical tests carried out in each sample were CA-125, ADA and 5'-NT. Serum CA-125 was estimated by Microparticulated enzymatic immunoassay (MEIA) method in the AxSym analyzer of Abbott Laboratories, USA. Serum ADA was estimated by the colorimetric method of Giusti (7) in which Adenosine is used as the substrate and the ammonia liberated is measured as blue indophenol. 5'-NT was estimated by the colorimetric method of Raymond John and David Gwynne Williams (8) in which 5'-adenosine monophosphate (5'-AMP) was used as the substrate and the liberated phosphate is measured. Nickel was used to differentiate the activities of alkaline phosphatase and 5'-NT.
Chemicals
All general chemicals were of reagent grade. Adenosine was purchased from SISCO Research Laboratories, India. 5'-AMP disodium salt was purchased from E-Merck, Germany.
Statistical analysis
Statistical analysis was done using the student's 't' test. Comparisons were made between controls and the benign group, between the control group and the cancer group and also between the benign group and the cancer group. Correlation was analysed between CA 125, ADA and 5'-NT including both cancer group and benign group in the analysis.
RESULTS
The CA 125 values in serum ranged from 71-6,000 U/ml in the ovarian cancer group (Ca ovary) and 3-61 U/ml in the benign group.
There was a marked increase in ADA levels in the ovarian cancer group when compared to controls (P<0.001, Table 1 ) and when compared to the benign group (not significant). However, there was no difference in the ADA levels in the benign group when compared to the controls. The sensitivity of ADA as a tumour marker was found to be 56% and the specificity was 78%. The cut-off value for ADA was taken as 30 U/L which is the upper limit of the range obtained for healthy controls.
The mean serum 5'-NT value was found to be elevated in ovarian cancer group when compared to both the control and the benign group (Table 1) even though there was no statistical significance. The sensitivity and specificity of 5'-NT estimation was calculated to be 38% and 86% respectively. The cut-off value for 5'-NT was taken as 18 U/L, the upper limit of the range obtained for healthy controls.
No significant correlation was observed between CA 125 and ADA and between CA 125 and 5'-NT.
DISCUSSION
The results of the present study show that both ADA and 5'-NT levels are increased only in ovarian cancer but not in the benign group. These findings suggest that the elevated levels are certainly due to the presence of cancer cells. Hence these two parameters can serve as tumour markers and may be useful in differentiating ovarian cancer from benign tumours of the ovary, in addition to the wellestablished marker of ovarian cancer, CA-125. However, detailed study of ADA and 5'-NT is required considering the various stages of cancer as well as pre and pOst-therapeutic changes to confirm their clinical utility in the management of ovarian cancer. The statistical significance and sensitivity and s1~ecificity studies indicate that ADA is a better parameter than 5'-NT in the study of ovarian cancer. 
